BRAF and melanoma: The anti-proliferative effects of both SR4 and niclosamide were evaluated in melanoma cells with wild type BRAF (Mewo, SK-MEL-2), BRAFV600E (A101D, A375, A2058, SK-MEL5, SK-MEL-28) and NRAS (SK-MEL-2) mutations using the Cell Titer Glo cell viability assay.